Updates are available Correction dated 2022-04-05
Click to view Correction: https://doi.org/10.1038/s41598-022-10024-2
-
Authors
Yun, Sung-Il
Lee, Sang-Kyu
Goh, Eun-Ah
Kwon, Oh Seung
Choi, Woorim
Kim, Jangseon
Lee, Mi Sun
Choi, Soon Ja
Lim, Seung Sik
Moon, Tae Kee
Kim, Sin Hae
Kyong, Keeyeol
Nam, Gaewon
Park, Han-Oh
-
Funding
Funding for this research was provided by:
Ministry of Small and Medium-sized Enterprises (SMEs) and Startups (MSS), Korea, under the “Regional Specialized Industry Development Program (R&D, P0003166)
- License Information
-
More Information
Article History
Received: 9 August 2021
Accepted: 11 January 2022
First Online: 31 January 2022
Change Date: 5 April 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-022-10024-2
Competing interests
: Sung-Il Yun and Seung Sik Lim are employees of Bioneer Corporation. Sang-Kyu Lee, Eun-Ah Goh, Oh Seung Kwon, Woorim Choi, Jangseon Kim, Mi Sun Lee and Soon Ja Choi are employees of siRNAgen Therapeutics. Han-Oh Park is the Chief Executive Officer of Bioneer Corporation and siRNAgen Therapeutics. Tae Kee Moon and Sin Hae Kim are employees of Ellead Skin Research Center, Keeyeol Kyong and Gaewon Nam are employees of Seowon University. Bioneer Corporation funded the clinical study II.
